Parkinson’s disease is primarily caused due to reduced levels of dopamine – a neurotransmitter that relays signals between the substantia nigra and other brain parts to control movements. WHO estimated the worldwide number of people afflicted with Parkinson’s disease in 2012 to be more than 10 million, worldwide. Parkinson’s disease mainly affects the middle-aged and elderly. Geriatric population which was 7% in 2000 is set to increase to 16% in 2050, possibly creating future demand for
Parkinson’s disease therapeutics. According to a recent study by Hexa Research, growing number of people afflicted with Parkinson’s disease across the globe will drive the market for Parkinson’s disease therapeutics. Complications arising out of Parkinson’s disease are the 14th top cause of death in US.
Browse Detailed Report with TOC at:
http://www.hexareports.com/report/parkinsons-disease-therapeutics-market/details
Hexa Research notes that the total Parkinson’s disease therapeutics market can be divided into four segments – drug therapy, deep brain stimulation devices, ablative neurosurgery and others. Drug therapy is the choice of treatment and accounts for the largest share of the market at present. However, its demand will get adversely affected by the expiry of patents of widely-used drugs like Comtan/Stalevo/Comtess by Novartis/Orion Pharma, and Azilect/Agilect by Teva Pharmaceuticals/Lundbeck.
However, the resultant losses will get compensated by a strong drug pipeline like IPX-066 from Impax Laboratories/GlaxoSmithKline, safinamide from Merck Sereno/EMD Sereno/Neuron Pharmaceutical and istradefylline from Kyowa Hakko Kirin in future.
Healthcare Market Research Reports Related Reports:
Global Industrial X-ray Film Industry 2015:
http://www.hexareports.com/report/global-industry-x-ray-film-industry
Disposable Medical Supplies Industry Forecasts:
http://www.hexareports.com/report/disposable-medical-supplies-industry-forecasts-china-focus
Alternative therapeutic options like deep brain stimulation devices and a large untapped consumer base in emerging markets like India, China and Brazil are also
expected to boost growth of the global Parkinson’s disease therapeutics industry.
Table of Contents
Chapter 1. Executive Summary
Chapter 2. Parkinson’s Disease Therapeutics Market Analysis
2.1. Market Segmentation
2.2. Value Chain Analysis
2.3. Market Drivers and Restraints
2.4. Parkinson’s Disease Therapeutics – Porter’s Analysis
2.5. Parkinson’s Disease Therapeutics – SWOT Analysis
2.6. Parkinson’s Disease Therapeutics - Company Market Share Analysis
Chapter 3. Parkinson’s Disease Therapeutics Market Size, By Product
3.1. Drug Therapy
3.1.1. Dopamine Replacement Therapy (DRT)
3.1.1.1. Global DRT market, 2012 – 2019, (USD Million)
3.1.2. Dopamine Agonists
3.1.2.1. Global dopamine agonists market, 2012 – 2019, (USD Million)
3.1.3. MAO-inhibitors
Request a sample copy of this Report at:
http://www.hexareports.com/sample/46083
Chapter 4. Parkinson’s Disease Therapeutics Market Size, By Region
4.1. North America
4.1.1. North America Parkinson’s disease therapeutics market, by product, 2012 – 2019, (USD Million)
4.2. Europe
4.2.1. Europe Parkinson’s disease therapeutics market, by product, 2012 – 2019, (USD Million)
4.3. Asia Pacific
4.3.1. Asia Pacific Parkinson’s disease therapeutics market, by product, 2012 – 2019, (USD Million)
4.4. RoW
4.4.1. RoW Parkinson’s disease therapeutics market, by product, 2012 – 2019, (USD Million)
Chapter 5. Key Company Profiles
5.1. Novartis
5.1.1. Company overview
5.1.2. Product portfolio
5.1.3. Financial overview
5.1.4. Recent developments
5.2. Teva Pharmaceuticals
5.2.1. Company overview
For More Detailed Report Visit:
http://www.hexareports.com/report/parkinsons-disease-therapeutics-market/details
About Us:
Hexa Reports Inc. is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe.We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.
Media ContactCompany Name: Hexa Reports
Contact Person: Ryan Shaw
Email:Send Email
Phone: 1-800-489-3075
Address:Felton Office Plaza, 6265 Highway 9
City: Felton
State: California
Country: United States
Website: http://www.hexareports.com/report/parkinsons-disease-therapeutics-market/details
